Green tea polyphenols attenuate hepatic steatosis, and reduce insulin resistance and inflammation in high-fat diet-induced rats

Xia,Hong‑Miao; Wang,Jin; Xie,Xiao‑Jie; Xu,Li‑Juan; Tang,Shi‑Qi

doi:10.3892/ijmm.2019.4285

Green tea polyphenols attenuate hepatic steatosis, and reduce insulin resistance and inflammation in high-fat diet-induced rats

Authors:
- Hong‑Miao Xia
- Jin Wang
- Xiao‑Jie Xie
- Li‑Juan Xu
- Shi‑Qi Tang
View Affiliations

Affiliations: Medical Examination Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: July 23, 2019 https://doi.org/10.3892/ijmm.2019.4285
Pages: 1523-1530

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, insulin resistance and inflammation; however, the exact pathogenesis of NAFLD is not fully understood. Green tea polyphenols (GTP) exhibit beneficial effects against metabolic syndrome. However, the effect of GTP on NAFLD remains largely unknown. The aim of the present study was to investigate the effects of GTP on NAFLD in high‑fat diet (HFD)‑induced rats. The NAFLD rat model was induced with a HFD for 8 weeks. A total of 30 adult male Sprague Dawley rats were randomly divided into three groups: i) Normal control group; ii) HFD group; and iii) HFD with GTP group. Hematoxylin and eosin and Oil Red O analyses were performed. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory cytokines in the serum, as well as oxidative stress markers and hepatic lipids in the liver were measured. In addition, parameters associated with glucose metabolism were also assessed. Western blotting and RT‑qPCR were used to determine the expression levels of 5' adenosine monophosphate‑activated protein kinase (AMPK). HFD‑induced rats exhibited features associated with NAFLD. GTP intervention significantly reduced serum ALT and AST levels. Fasting serum glucose, insulin resistance and hepatic lipid levels were all decreased in the GTP‑treated rats. GTP also significantly decreased the levels of TNF‑α, IL‑6 and malondialdehyde. In contrast, superoxide dismutase levels were increased in the liver. Furthermore, GTP also significantly increased phosphorylation of AMPK and attenuated histopathological changes indicative of injury in liver tissue. GTP has a protective effect on HFD‑induced hepatic steatosis, insulin resistance and inflammation, and the underlying mechanism may involve the AMPK pathway.

View Figures

View References

1	Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM, Ki SH, Kim CE, Park KI, Kim SC and Kim YW: Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Chem Biol Interact. 289:68–74. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM and Sanyal AJ: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 67:328–357. 2018. View Article : Google Scholar
3	Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL and Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 140:124–131. 2011. View Article : Google Scholar
4	Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, et al: Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 61:409–415. 2012. View Article : Google Scholar
5	Luo P, Qin C, Zhu L, Fang C, Zhang Y, Zhang H, Pei F, Tian S, Zhu XY, Gong J, et al: Ubiquitin-specific peptidase 10 (USP10) inhibits hepatic steatosis, insulin resistance, and inflammation through Sirt6. Hepatology. 68:1786–1803. 2018. View Article : Google Scholar : PubMed/NCBI
6	Anstee QM, Targher G and Day CP: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 10:330–344. 2013. View Article : Google Scholar : PubMed/NCBI
7	Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ and Shulman GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 279:32345–32353. 2004. View Article : Google Scholar : PubMed/NCBI
8	Savage DB, Petersen KF and Shulman GI: Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 87:507–520. 2007. View Article : Google Scholar : PubMed/NCBI
9	El-Sherbiny M, Eldosoky M, El-Shafey M, Othman G, Elkattawy HA, Bedir T and Elsherbiny NM: Vitamin D nano-emulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet. Chem Biol Interact. 288:65–75. 2018. View Article : Google Scholar : PubMed/NCBI
10	Day CP: Non-alcoholic fatty liver disease: A massive problem. Clin Med (Lond). 11:176–178. 2011. View Article : Google Scholar
11	Ding S, Jiang J, Zhang G, Bu Y, Zhang G and Zhao X: Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PLoS One. 12:e01835412017. View Article : Google Scholar : PubMed/NCBI
12	Rotman Y and Sanyal AJ: Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 66:180–190. 2017. View Article : Google Scholar
13	Sabu MC, Smitha K and Kuttan R: Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol. 83:109–116. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kim JJ, Tan Y, Xiao L, Sun YL and Qu X: Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed Res Int. 2013:9201282013. View Article : Google Scholar : PubMed/NCBI
15	Lubaczeuski C, Gonçalves LM, Vettorazzi JF, Kurauti MA, Santos-Silva JC, Bonfleur ML, Boschero AC, Costa-Júnior JM and Carneiro EM: Vagotomy reduces insulin clearance in obese mice programmed by low-protein diet in the adolescence. Neural Plast. 2017:96529782017. View Article : Google Scholar : PubMed/NCBI
16	Kalantar M, Kalantari H, Goudarzi M, Khorsandi L, Bakhit S and Kalantar H: Crocin ameliorates methotrexate-induced liver injury via inhibition of oxidative stress and inflammation in rats. Pharmacol Rep. 71:746–752. 2019. View Article : Google Scholar : PubMed/NCBI
17	Jiang S, Tang X, Wang K, Liang Y, Qian Y, Lu C and Cai L: Hepatic functional and pathological changes of type 1 diabetic mice in growing and maturation time. J Cell Mol Med. Jun 20–2019, (Epub ahead of print). http://doi.org/10.1111/jcmm.14504urisimpledoi.org/10.1111/jcmm.14504. View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Tilg H and Moschen AR: Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 19:371–379. 2008. View Article : Google Scholar : PubMed/NCBI
20	Gong J, Fang C, Zhang P, Wang PX, Qiu Y, Shen LJ, Zhang L, Zhu XY, Tian S, Li F, et al: Tumor progression locus 2 in hepatocytes potentiates both liver and systemic metabolic disorders in mice. Hepatology. 69:524–544. 2019. View Article : Google Scholar
21	Zhao GN, Zhang P, Gong J, Zhang XJ, Wang PX, Yin M, Jiang Z, Shen LJ, Ji YX, Tong J, et al: Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. Nat Med. 23:742–752. 2017. View Article : Google Scholar : PubMed/NCBI
22	Kitade H, Chen G, Ni Y and Ota T: Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments. Nutrients. 9:pii: E387. 2017. View Article : Google Scholar : PubMed/NCBI
23	Samuel VT and Shulman GI: Mechanisms for insulin resistance: Common threads and missing links. Cell. 148:852–871. 2012. View Article : Google Scholar : PubMed/NCBI
24	Arora A and Sharma P: Non-invasive diagnosis of fibrosis in non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2:145–155. 2012. View Article : Google Scholar : PubMed/NCBI
25	Podrini C, Borghesan M, Greco A, Pazienza V, Mazzoccoli G and Vinciguerra M: Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). Curr Pharm Des. 19:2737–2746. 2013. View Article : Google Scholar
26	Reddy VP, Zhu X, Perry G and Smith MA: Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis. 16:763–774. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kishimoto T: IL-6: From its discovery to clinical applications. Int Immunol. 22:347–352. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lesmana CR, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N and Lesmana LA: Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J Dig Dis. 10:201–206. 2009. View Article : Google Scholar : PubMed/NCBI
29	Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML and Tipoe GL: Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr. 53:187–199. 2014. View Article : Google Scholar
30	Wen H, Ting JP and O'Neill LA: A role for the NLRP3 inflam-masome in metabolic diseases-did Warburg miss inflammation? Nat Immunol. 13:352–357. 2012. View Article : Google Scholar : PubMed/NCBI
31	Park MH, Kim DH, Lee EK, Kim ND, Im DS, Lee J, Yu BP and Chung HY: Age-related inflammation and insulin resistance: A review of their intricate interdependency. Arch Pharm Res. 37:1507–1514. 2014. View Article : Google Scholar : PubMed/NCBI
32	Guturu P and Duchini A: Etiopathogenesis of nonalcoholic steatohepatitis: Role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol. 2012:2128652012. View Article : Google Scholar : PubMed/NCBI
33	Jones JG: Hepatic glucose and lipid metabolism. Diabetologia. 59:1098–1103. 2016. View Article : Google Scholar : PubMed/NCBI
34	Lambert JE, Ramos-Roman MA, Browning JD and Parks EJ: Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 146:726–735. 2014. View Article : Google Scholar
35	Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ and Steinberg GR: Treatment of nonalcoholic fatty liver disease: Role of AMPK. Am J Physiol Endocrinol Metab. 311:E730–E740. 2016. View Article : Google Scholar : PubMed/NCBI
36	Chiu CY, Chan IL, Yang TH, Liu SH and Chiang MT: Supplementation of chitosan alleviates high-fat diet-enhanced lipogenesis in rats via adenosine monophosphate (AMP)-activated protein kinase activation and inhibition of lipogenesis-associated genes. J Agric Food Chem. 63:2979–2988. 2015. View Article : Google Scholar : PubMed/NCBI
37	Cho YS, Lee JI, Shin D, Kim HT, Jung HY, Lee TG, Kang LW, Ahn YJ, Cho HS and Heo YS: Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK. Biochem Biophys Res Commun. 391:187–192. 2010. View Article : Google Scholar
38	Choi S, Choi Y, Choi Y, Kim S, Jang J and Park T: Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice. Food Chem. 141:3627–3635. 2013. View Article : Google Scholar : PubMed/NCBI